{"id":476159,"date":"2020-03-25T13:50:01","date_gmt":"2020-03-25T13:50:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=476159"},"modified":"2020-03-25T13:50:01","modified_gmt":"2020-03-25T13:50:01","slug":"sickle-cell-disease-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sickle-cell-disease-analysis-market-size-epidemiology-leading-companies-and-competitive-analysis-by-delveinsight_476159.html","title":{"rendered":"Sickle Cell Disease Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis By DelveInsight"},"content":{"rendered":"
\"Sickle<\/a><\/div>\n

DelveInsight has launched a new report on Sickle Cell Disease Market Insights, Epidemiology and Market Forecast-2030<\/strong><\/p>\n

DelveInsight’s “Sickle Cell Disease – Market Insights, Epidemiology, and Market Forecast-2030″<\/span> report delivers an in-depth understanding of the Sickle Cell Disease, historical and forecasted epidemiology as well as the Sickle Cell Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n

The Sickle Cell Disease market report provides current treatment practices, emerging drugs, Sickle Cell Disease market share of the individual therapies, current and forecasted Sickle Cell Disease market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Sickle Cell Disease treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n

Sickle cell disease (SCD) is an inherited red blood cell disorder caused by a structural abnormality of hemoglobin called sickle hemoglobin (HbS) which encodes hemoglobin subunit β. HbS is inherited in an autosomal recessive way and can occur due to homozygosity for HbS (HbSS). HbS is functional and soluble when oxygenated, but upon deoxygenation it polymerizes, leading to the generation of deformed red blood cells known as sickled cells and dense erythrocytes. According to the Centre of Disease Control and Prevention (CDC), it is estimated that SCD affects approximately 100,000 Americans. It occurs among about 1 out of every 365 Black or African-American births, about 1 out of every 16,300 Hispanic-American births, and about 1 in 13 Black or African-American babies is born with sickle cell trait.<\/div>\n
 <\/div>\n
\"\"<\/div>\n
 <\/div>\n
Request for :- sickle cell disease free sample disease<\/a><\/div>\n
 <\/div>\n
Sickle Cell Disease Epidemiology  <\/strong><\/p>\n

The Sickle Cell Disease epidemiology division provide insights about historical and current Sickle Cell Disease <\/span>patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. <\/p>\n

Sickle Cell Disease Drug Chapters<\/strong><\/p>\n

Drug chapter segment of the Sickle Cell Disease report encloses the detailed analysis of Sickle Cell Disease marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Sickle Cell Disease <\/span>clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.<\/p>\n

Sickle Cell Disease Market Outlook<\/strong><\/p>\n

The Sickle Cell Disease market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Sickle Cell Disease <\/span>market <\/span>trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. <\/p>\n

 <\/p>\n

key companies working on sickle cell disease that are given below<\/span><\/strong><\/p>\n<\/div>\n

1. Pfizer Inc<\/span><\/div>\n
2. Micelle BioPharma Inc<\/span><\/div>\n
3. AstraZeneca<\/span><\/div>\n
 <\/div>\n
Drugs covered of sickel cell disease are given below:- <\/strong><\/div>\n
 <\/div>\n
1. Rivipansel<\/span><\/div>\n
2. SC411 (Altemia)<\/span><\/div>\n
3. Ticagrelor<\/span><\/div>\n
 <\/div>\n
Table of contents<\/a><\/div>\n
\n

1. Key Insights<\/span><\/p>\n

2. Executive Summary of Sickle Cell Disease<\/span><\/p>\n

3. Competitive Intelligence Analysis for Sickle Cell Disease<\/span><\/p>\n

4. Sickle Cell Disease: Market Overview at a Glance<\/span><\/p>\n

4.1. Sickle Cell Disease Total Market Share (%) Distribution in 2017<\/span><\/p>\n

4.2. Sickle Cell Disease Total Market Share (%) Distribution in 2030<\/span><\/p>\n

5. Sickle Cell Disease: Disease Background and Overview<\/span><\/p>\n

6. Patient Journey<\/p>\n

7. Sickle Cell Disease Epidemiology and Patient Population<\/span><\/p>\n

8. Treatment Algorithm, Current Treatment, and Medical Practices<\/span><\/p>\n

8.1. Sickle Cell Disease Treatment and Management<\/span><\/p>\n

8.2. Sickle Cell Disease Treatment Algorithm <\/span><\/p>\n

9. Unmet Needs<\/span><\/p>\n

10. Key Endpoints of Sickle Cell Disease Treatment<\/span><\/p>\n

11. Marketed Products<\/span><\/p>\n

12. Emerging Therapies<\/span><\/p>\n

13. Sickle Cell Disease: Seven Major Market Analysis<\/span><\/p>\n

13.1. Key Findings<\/span><\/p>\n

13.2. Sickle Cell Disease Market Size in 7MM<\/span><\/p>\n

13.3. Sickle Cell Disease Market Size by Therapies in the 7MM<\/span><\/p>\n

14. Attribute analysis<\/span><\/p>\n

15. 7MM: Market Outlook<\/span><\/p>\n

16. Access and Reimbursement Overview of Sickle Cell Disease<\/p>\n

17. KOL Views<\/span><\/p>\n

18. Market Drivers<\/span><\/p>\n

19. Market Barriers<\/span><\/p>\n

20. Appendix<\/span><\/p>\n

20.1. Bibliography<\/span><\/p>\n

20.2. Report Methodology<\/span><\/p>\n

21. DelveInsight Capabilities<\/span><\/p>\n

22. Disclaimer<\/span><\/p>\n

23. About<\/strong> DelveInsight<\/a><\/p>\n<\/div>\n

Why should you buy this report ?<\/strong><\/div>\n
\n